Citius Oncology (CTOR) EBIT (2023 - 2026)

Citius Oncology (CTOR) has reported EBIT for 4 consecutive years, with -$8.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 76.28% year-over-year to -$8.7 million in Q2 2026; TTM through Jun 2026 was -$47.3 million, a 44.56% decrease from a year earlier, with the FY2025 full-year figure at -$23.5 million, down 14.34% from the prior year.
• EBIT was -$8.7 million for Q2 2026 at Citius Oncology, up from -$28.6 million in the prior quarter.
• Over five years, EBIT peaked at -$147922.0 in Q1 2023 and troughed at -$28.6 million in Q1 2026.
• A 4-year average of -$6.6 million and a median of -$4.9 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 6867.44% in 2024 and surged 64.43% in 2025, its largest moves.
• Over 4 years, EBIT stood at -$4.6 million in 2023, then slumped by 39.52% to -$6.4 million in 2024, then increased by 17.87% to -$5.3 million in 2025, then sank by 65.96% to -$8.7 million in 2026.
• The last three EBIT figures came in at -$8.7 million (Q2 2026), -$28.6 million (Q1 2026), and -$5.3 million (Q4 2025), per Business Quant data.